Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 May;5(5):475-87.
doi: 10.1158/2159-8290.CD-15-0011. Epub 2015 Apr 20.

The BCL2 Family: Key Mediators of the Apoptotic Response to Targeted Anticancer Therapeutics

Aaron N Hata  1 , Jeffrey A Engelman  2 , Anthony C Faber  3
Affiliations
Review

The BCL2 Family: Key Mediators of the Apoptotic Response to Targeted Anticancer Therapeutics

Aaron N Hata et al. Cancer Discov. 2015 May.

Abstract

The ability of cancer cells to suppress apoptosis is critical for carcinogenesis. The BCL2 family proteins comprise the sentinel network that regulates the mitochondrial or intrinsic apoptotic response. Recent advances in our understanding of apoptotic signaling pathways have enabled methods to identify cancers that are "primed" to undergo apoptosis, and have revealed potential biomarkers that may predict which cancers will undergo apoptosis in response to specific therapies. Complementary efforts have focused on developing novel drugs that directly target antiapoptotic BCL2 family proteins. In this review, we summarize the current knowledge of the role of BCL2 family members in cancer development and response to therapy, focusing on targeted therapeutics, recent progress in the development of apoptotic biomarkers, and therapeutic strategies designed to overcome deficiencies in apoptosis.

Significance: Apoptosis, long known to be important for response to conventional cytotoxic chemotherapy, has more recently been shown to be essential for the efficacy of targeted therapies. Approaches that increase the likelihood of a cancer to undergo apoptosis following therapy may help improve targeted treatment strategies. Cancer Discov; 5(5); 475-87. ©2015 AACR.

PubMed Disclaimer

Figures

Figure 1
Figure 1. The intrinsic apoptotic pathway is regulated by BCL-2 family proteins at the level of the mitochondria
Multiple cellular stressors modulate the expression levels of pro- and anti-apoptotic BCL-2 family proteins (red and green respectively), leading to the activation of BAX and/or BAK and mitochondrial depolarization.
Figure 2
Figure 2. Targeted therapies inhibit oncogenic kinase signaling cascades and modulate BCL-2 family proteins to induce apoptosis
Examples of commonly occuring cancers driven by specific oncogenic driver mutations that result in constitutively activated downstream kinase signaing pathways and suppression of the mitochondrial apoptotic pathway. By inhibiting these pathways, targeted therapies lead to upregulation of pro-apoptotic BH3-only proteins and/or downregulation of pro-survival BCL-2 family proteins, ultimately inducing apoptosis. (See references: EGFR (84, 87, 88, 105, 108), BRAF (89, 106, 181), KRAS (90), CML (76, 91, 113))
Figure 3
Figure 3. Strategies for enhancing the pro-apoptotic activity of BIM
Demethylating agents or histone deacetylase (HDAC) inhibitors may overcome epigenetic reppression of BIM transcription, whereas MEK inhibitors (e.g. trametinib) decrease BIM degradation—all leading to increased cellular BIM protein levels and increased activation of BAX. BCL-2/BCL-XL inhibitors (e.g. navitoclax) block the ability for anti-apoptotic BCL-2 family members like BCL-2 and BCL-XL to neutralize BIM.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Reed JC. Dysregulation of apoptosis in cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1999;17:2941–53. - PubMed
    1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–74. - PubMed
    1. Tsujimoto Y, Finger LR, Yunis J, Nowell PC, Croce CM. Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation. Science. 1984;226:1097–9. - PubMed
    1. Cleary ML, Sklar J. Nucleotide sequence of a t(14;18) chromosomal breakpoint in follicular lymphoma and demonstration of a breakpoint-cluster region near a transcriptionally active locus on chromosome 18. Proc Natl Acad Sci U S A. 1985;82:7439–43. - PMC - PubMed
    1. Bakhshi A, Jensen JP, Goldman P, Wright JJ, McBride OW, Epstein AL, et al. Cloning the chromosomal breakpoint of t(14;18) human lymphomas: clustering around JH on chromosome 14 and near a transcriptional unit on 18. Cell. 1985;41:899–906. - PubMed

Publication types

MeSH terms